Paper Details

  1. Home
  2. Paper Details

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.

Author: , BertagnolioSilvia, EasterbrookPhilippa J, HoppeAnne, KityoCissy, MambuleIvan, MugyenyiPeter, NankyaImmaculate, NdashimyeEmmanuel, PatonNicholas I, ThompsonJennifer, WalkerA Sarah, WarambwaColin, Wools-KaloustianKara, van OosterhoutJoep J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study determined drug resistance mutation (DRM) patterns in a large cohort of patients failing nonnucleoside reverse transcriptase inhibitor (NNRTI)-based first-line antiretroviral therapy regimens in programs without routine viral load (VL) monitoring. The study found that non-B subtypes differ in DRMs at first-line failure, which impacts on residual nucleoside reverse transcriptase inhibitor and NNRTI susceptibility.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To determine drug resistance mutation (DRM) patterns in a large cohort of patients failing nonnucleoside reverse transcriptase inhibitor (NNRTI)-based first-line antiretroviral therapy regimens in programs without routine viral load (VL) monitoring and to examine intersubtype differences ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427983/

データ提供：米国国立医学図書館（NLM）

HIV Drug Resistance: Navigating the Shifting Sands of Sub-Saharan Africa

The fight against HIV in Sub-Saharan Africa is a relentless battle, with drug resistance posing a significant challenge. This study explores the patterns of drug resistance mutations (DRMs) among patients in Sub-Saharan Africa who have failed first-line antiretroviral therapy. This research is like a team of explorers carefully mapping the changing landscape of HIV drug resistance, understanding its complex patterns and implications. The study focuses on non-B subtypes of HIV, a group that is particularly challenging to treat.

Understanding the Complex Landscape of HIV Resistance

The study reveals interesting differences in DRM patterns across different HIV subtypes. The findings suggest that some subtypes are more prone to developing resistance to specific drugs, like etravirine and rilpivirine. This is like discovering that certain areas in the desert have unique challenges for travelers, requiring different approaches to navigation. This information is critical for adapting treatment strategies to ensure effective therapy for individuals with different subtypes.

Developing Effective Treatment Strategies

This study highlights the importance of understanding the specific characteristics of different HIV subtypes to effectively combat drug resistance. By carefully analyzing the patterns of DRMs, researchers can develop more tailored treatment approaches to improve patient outcomes. This is like adapting travel plans based on the specific challenges of a particular desert region, ensuring a safer and more successful journey.

Dr. Camel's Conclusion

This study illuminates the complex and evolving landscape of HIV drug resistance in Sub-Saharan Africa. By understanding the unique patterns of DRMs across different subtypes, researchers can develop more tailored treatment strategies to combat this persistent challenge. This is like a group of travelers studying the shifting sands of a desert, adapting their strategies to ensure a successful and safe journey through this challenging terrain.

Date :
  1. Date Completed 2017-06-23
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

28129253

DOI: Digital Object Identifier

PMC5427983

Related Literature

Article Analysis
・Effects of etravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.